Abstract

We analyzed SARS-CoV-2 seroprevalence in a large, well-described representative Viennese cohort after an early governmental lockdown with respect to the occurrence of symptoms and household transmission. Participants of the LEAD Study, a population-based cohort study from Vienna, Austria, were invited along with their household members (April 20th to May20th 2020). Sera were analyzed using anti-SARS-CoV-2 immunoassay including a neutralization test as a confirmatory assay. A total of 12,419 individuals participated (5984 LEAD participants; 6435 household members), 163 (1.31%; 59 LEAD cohort members) of whom were SARS-CoV-2 antibody positive. The estimated number of COVID-19 cases projected from our findings by age and sex for Vienna was 21,504 (1.13%). Cumulative number of positively tested cases in Vienna until May 20th 2020 was 3020, hence 7.1 times (95% confidence interval 5.5–9.1) lower than projected. Relative risk (RR) of seropositivity by age was highest for children aged 6–9 years [RR compared to age group 20–49: 1.21 (CI 0.37–4.01)], lowest for ≥ 65 years [RR 0.47 (CI 0.21–1.03)]. Half of the positive individuals developed no or mild symptoms. In a multivariate analysis, taste and smell disturbances were most strongly related to SARS-CoV-2 positivity. Infection probability within households with one confirmed SARS-CoV-2-specific antibody-positive person was 31%. Although seroprevalence was very low (1.13%) for a central European capital city, due to an early governmental lockdown, SARS-CoV-2 infections were more prevalent than officially reported polymerase chain reaction-positive cases. Of note, seroprevalence was highest in young children. Half of SARS-CoV-2 antibody-positive subjects had no or only mild symptoms. Taste and smell disturbances were most prominent, possibly guiding clinicians in diagnosing SARS-CoV-2 infection.

Details

Title
Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown
Author
Marie-Kathrin, Breyer 1   VIAFID ORCID Logo  ; Breyer-Kohansal Robab 2 ; Hartl, Sylvia 3 ; Kundi, Michael 4 ; Weseslindtner Lukas 5 ; Stiasny Karin 5 ; Puchhammer-Stöckl Elisabeth 5 ; Schrott, Andrea 6 ; Födinger Manuela 7 ; Binder, Michael 8 ; Fiedler, Markus 9 ; Wouters Emiel F M 9 ; Burghuber, Otto C 10 

 Clinic Penzing, Department of Respiratory and Critical Care Medicine, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Klink Penzing, Ludwig Boltzmann Institute for Lung Health, The Austrian LEAD Study, Vienna, Austria 
 Clinic Penzing, Department of Respiratory and Critical Care Medicine, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria 
 Clinic Penzing, Department of Respiratory and Critical Care Medicine, Vienna, Austria; Ludwig Boltzmann Institute for Lung Health, Vienna, Austria; Sigmund Freud University, Faculty of Medicine, Vienna, Austria (GRID:grid.263618.8) (ISNI:0000 0004 0367 8888) 
 Medical University of Vienna, Center for Public Health, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492) 
 Medical University of Vienna, Center for Virology, Vienna, Austria (GRID:grid.22937.3d) (ISNI:0000 0000 9259 8492) 
 Ludwig Boltzmann Institute for Lung Health, Vienna, Austria (GRID:grid.22937.3d) 
 Sigmund Freud University, Faculty of Medicine, Vienna, Austria (GRID:grid.263618.8) (ISNI:0000 0004 0367 8888); Clinic Favoriten, Institute of Laboratory Diagnostics, Vienna, Austria (GRID:grid.263618.8) 
 Vienna Healthcare Group, Vienna, Austria (GRID:grid.263618.8) 
 Ludwig Boltzmann Institute for Lung Health, Vienna, Austria (GRID:grid.263618.8) 
10  Ludwig Boltzmann Institute for Lung Health, Vienna, Austria (GRID:grid.263618.8); Sigmund Freud University, Faculty of Medicine, Vienna, Austria (GRID:grid.263618.8) (ISNI:0000 0004 0367 8888) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2525889568
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.